WA
REGN icon

Waddell & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Waddell & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$965K Sell
1,548
-181
-10% -$123K 0.05% 140
2026
Q1 		$1.34M Buy
1,729
+544
+46% +$416K 0.08% 83
2025
Q4 		$915K Buy
1,185
+461
+64% +$313K 0.06% 100
2025
Q3 		$407K Buy
+724
New +$409K 0.03% 165

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Waddell & Associates's REGN Position: Q2 2026 in Review

Waddell & Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 10% in Q2 2026, selling an estimated $123K and leaving 1,548 shares worth $965K. The position accounts for 0.05% of the portfolio, ranked #140.

Waddell & Associates first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.34M in Q1 2026. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Waddell & Associates held 1,548 shares of Regeneron Pharmaceuticals worth $965K as of Q2 2026.
  • Waddell & Associates sold 181 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $123K.
  • Regeneron Pharmaceuticals made up 0.05% of Waddell & Associates's portfolio in Q2 2026, its #140 holding.
  • Waddell & Associates first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Waddell & Associates's Regeneron Pharmaceuticals position peaked at $1.34M in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.